Telix Pharmaceuticals Ltd
TLPPFDrugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
68Ga-PSMA-11
PCA
177Lu-DOTA-TLX591
Prostate Cancer
Fluciclovine F18
Prostate Adenocarcinoma
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Prostate Cancer
Zirconium Zr 89 Girentuximab
Clear Cell Renal Cell Carcinoma
177Lu girentuximab
Advanced Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
68Ga-PSMA-11 | Phase 3 | PCA | - | - |
177Lu-DOTA-TLX591 | Phase 2 | Prostate Cancer | - | - |
Fluciclovine F18 | Phase 2 | Prostate Adenocarcinoma | - | - |
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC | Phase 2 | Prostate Cancer | - | - |
Zirconium Zr 89 Girentuximab | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
177Lu girentuximab | Phase 2 | Advanced Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Telix Pharmaceuticals Ltd's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Telix Pharmaceuticals Ltd's (TLPPF) pipeline across Phase 3, Phase 2. Its lead program is 68Ga-PSMA-11 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Telix Pharmaceuticals Ltd's next FDA catalyst?→
Telix Pharmaceuticals Ltd's (TLPPF) next tracked catalyst is a Phase 3 expected January 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TLPPF biotech catalysts?→
Add TLPPF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Telix Pharmaceuticals Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.